Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

1(14%)

Results Posted

125%(5 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_2

57%

Ph phase_3

29%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 2Efficacy & side effects

4(66.7%)

Phase 3Large-scale testing

2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Active, not recruiting1

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 24 (66.7%)

Phase 32 (33.3%)

Trials by Status

terminated114%

active_not_recruiting114%

completed457%

enrolling_by_invitation114%

Recent Activity

1 active trials

Showing 5 of 7

active_not_recruitingphase_3

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

NCT03992430

enrolling_by_invitation

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

NCT06606340

terminatedphase_2

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

NCT03985878

completedphase_2

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

NCT03218995

completedphase_3

Study of Eteplirsen in DMD Patients

NCT02255552

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT03992430Phase 3

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

Active Not Recruiting

NCT06606340

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Enrolling By Invitation

NCT03985878Phase 2

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

Terminated

NCT03218995Phase 2

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

Completed

NCT02255552Phase 3

Study of Eteplirsen in DMD Patients

Completed

NCT02420379Phase 2

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Completed

NCT02286947Phase 2

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7